Ariane Dunant

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

Jean‐Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti et al. · Journal of Clinical Oncology · 2008 · 2.7K citations · Full text

Medicine, Oncology, Pharmacology +13

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Ken A. Olaussen, Ariane Dunant, Pierre Fouret et al. · New England Journal of Medicine · 2006 · 1.7K citations · Full text

Medicine, Molecular Biology, Oncology +16

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study

Maja Mockenhaupt, Cécile Viboud, Ariane Dunant et al. · Journal of Investigative Dermatology · 2007 · 998 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis

B. Sassolas, Cynthia Haddad, Maja Mockenhaupt et al. · Clinical Pharmacology & Therapeutics · 2010 · 729 citations

Pharmacy, Pharmacology, Causal Inference +15

Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case–control study (EuroSCAR)

Alexis Sidoroff, Ariane Dunant, Cécile Viboud et al. · British Journal of Dermatology · 2007 · 567 citations

Medicine, Dermatology, Pharmacology +15